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The sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) is an intracellular membrane
transporter that utilizes the free energy provided by ATP hydrolysis for active transport of
Ca2+ ions from the cytoplasm to the lumen of sarco(endo)plasmic reticulum. SERCA
plays a fundamental role for cell calcium homeostasis and signaling in muscle cells
and also in cells of other tissues. Because of its prominent role in many physiological
processes, SERCA dysfunction is associated to diseases displaying various degrees
of severity. SERCA transport activity can be inhibited by a variety of compounds with
different chemical structures. Specific SERCA inhibitors were identified which have been
instrumental in studies of the SERCA catalytic and transport mechanism. It has been
proposed that SERCA inhibition may represent a novel therapeutic strategy to cure
certain diseases by targeting SERCA activity in pathogens, parasites and cancer cells.
Recently, novel small molecules have been developed that are able to stimulate SERCA
activity. Such SERCA activators may also offer an innovative and promising therapeutic
approach to treat diseases, such as heart failure, diabetes andmetabolic disorders. In the
present review the effects of pharmacologically relevant compounds on SERCA transport
activity are presented. In particular, we will discuss the interaction of SERCA with specific
inhibitors and activators that are potential therapeutic agents for different diseases.
Keywords: anticancer drug, antimalarial agent, drug-protein interaction, sarco(endo)plasmic reticulum Ca2+-
ATPase, SERCA activator, SERCA inhibitor, solid supported membrane
INTRODUCTION
P-type ATPases are membrane transporters that couple the energy provided by ATP hydrolysis
to the active transport of various ions or phospholipids. These enzymes generate and maintain
crucial electrochemical potential gradients across biological membranes (Kühlbrandt, 2004; Bublitz
et al., 2011). During their enzymatic cycle P-type ATPases form a phosphorylated intermediate by
interaction of ATP with a conserved aspartate residue at the catalytic domain.
The Ca2+-ATPase from sarco(endo)plasmic reticulum (SERCA), belonging to the PIIA-ATPase
subfamily, is an intracellular membrane-associated protein of approximately 110 KDa which is
involved in cell calcium signaling and homeostasis (Brini and Carafoli, 2009). In muscle cells this
enzyme hydrolyzes one ATP molecule to transport two Ca2+ ions against their electrochemical
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potential gradient from the cytoplasm to the lumen of
sarcoplasmic reticulum (SR) (Inesi and Tadini-Buoninsegni,
2014). SERCA therefore induces muscle relaxation by pumping
back cytosolic calcium into the SR lumen. SERCA isoforms
are involved in calcium signaling mechanisms for many
biological functions, e.g., excitation-contraction coupling,
excitation-secretion coupling, gene transcription, and apoptotic
mechanisms. Because of its pivotal role, alterations in SERCA
expression and impaired pump function have been related to
several diseases, such as Brody’s disease, Darier’s disease, heart
failure, cancer, and diabetes (Brini and Carafoli, 2009).
The SERCA enzyme is one of the best investigated membrane
transporter. Its structure comprises three distinct cytoplasmic
domains, i.e., the A (actuator), N (nucleotide binding), and P
(phosphorylation) domains, and a transmembrane region of 10
helical segments (TM1–TM10) including the two Ca2+ binding
sites. SERCA transport cycle is described by the E1-E2 scheme
(de Meis and Vianna, 1979). If one starts at the E1 state, the
ATPase cycle (Figure 1) begins with high affinity binding of two
Ca2+ ions derived from the cytosol, followed by phosphorylation
of the enzyme by ATP and formation of a high energy E1∼P
state. During relaxation from the E1∼P state to the lower energy
E2P state, Ca
2+ ions are translocated across the membrane
and released into the SR in exchange for luminal protons.
Hydrolytic cleavage of the phosphoenzyme (dephosphorylation)
is the final reaction step, which allows the enzyme to undergo
a new transport cycle. High resolution crystal structures of
various conformational states in the SERCA transport cycle were
obtained, as described in detailed reviews (Toyoshima, 2008;
Møller et al., 2010; Bublitz et al., 2013; Toyoshima and Cornelius,
2013).
In this short review we will focus our attention on the
interaction of SERCA with specific inhibitors and activators
that may represent potential therapeutic agents for different
diseases. To investigate the effects of pharmacologically relevant
compounds on SERCA transport activity, we employ an
electrophysiological technique, which is discussed in the next
section.
DRUG INTERACTIONS INVESTIGATED BY
ELECTROPHYSIOLOGY BASED ON SOLID
SUPPORTED MEMBRANES
The ion transport mechanism of P-type ATPases, e.g., Na+,K+-
ATPase, SERCA, and Cu+-ATPases (ATP7A and ATP7B)
(Pintschovius et al., 1999; Tadini-Buoninsegni et al., 2008a;
Lewis et al., 2012; Inesi et al., 2014; Tadini-Buoninsegni and
Smeazzetto, 2017), was investigated by an electrophysiological
technique based on a solid supported membrane (SSM). In
particular, SSM-based electrophysiology was useful to identify
electrogenic steps and to assign rate constants to partial reactions
Abbreviations: Br2-TITU, 1,3-dibromo-2,4,6-tris(methyl-isothio-uronium)
benzene; DBHQ, 2,5-di(tert-butyl)hydroquinone; CPA, cyclopiazonic acid;
ER, endoplasmic reticulum; PLN, phospholamban; PSMA, prostate-specific
membrane antigen; SR, sarcoplasmic reticulum; SERCA, sarco(endo)plasmic
reticulum Ca2+-ATPase; SSM, solid supported membrane; TG, thapsigargin.
FIGURE 1 | Upper Panel: Schematic diagram of sequential reactions in the
transport cycle of SERCA. Lower Panel: SR vesicle adsorbed on a SSM and
subjected to an ATP concentration jump (not drawn to scale). If the ATP jump
induces net charge displacement, a compensating current flows along the
external circuit (the red spheres represent electrons) to keep constant the
potential difference 1V applied across the whole system. RE is the reference
electrode. Reprinted from Tadini-Buoninsegni et al. (2008a) with permission
from Elsevier.
in the transport cycle of P-type ATPases. In the case of Na+,K+-
ATPase SSM-based electrophysiology provided a direct proof
for the electrogenicity of Na+ binding to the cytoplasmic
side of the protein (Pintschovius et al., 1999). Also in the
case of SERCA SSM-based electrophysiology was employed
for a detailed characterization of the enzyme’s transport cycle,
especially as concerns Ca2+ binding and Ca2+/H+ exchange
(Tadini-Buoninsegni et al., 2006; Liu et al., 2009).
This technique makes use of a hybrid
alkanethiol/phospholipid bilayer supported by a gold electrode
(SSM, Figure 1; Pintschovius and Fendler, 1999). The SSM
is formed in two sequential self-assembly steps. First, an
octadecanethiol monolayer is obtained which is covalently
bound to the gold electrode via the sulfur atom. Then, a
second phosphatidylcholine monolayer is formed on top of
the thiol layer. Proteoliposomes, membrane fragments, or
vesicles containing the ATPase are adsorbed on the SSM surface
(Figure 1). Once adsorbed, the ATPasemolecules are activated by
a concentration jump of a specific substrate through fast solution
exchange. By rapidly changing from a solution containing
no substrate for the protein to one that contains a substrate,
the protein is activated and a current transient is detected,
which is related to charge displacement across the ATPase.
The transient nature of the current signal is a consequence of
the capacitively coupled system formed by the SSM and the
membrane entities adsorbed on it (Schulz et al., 2008; Tadini-
Buoninsegni and Bartolommei, 2016). In the case of SERCA,
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an ATP concentration jump on SERCA-containing vesicles
adsorbed on the SSM generates a current signal, that is related to
an electrogenic event corresponding to translocation and release
of bound Ca2+ upon phosphorylation by ATP within the first
enzyme cycle (Tadini-Buoninsegni et al., 2006). Therefore, the
SSM technique allows pre-steady state measurements of charge
displacements within the first transport cycle of the ATPase,
while steady-state currents are not measured.
SSM-based electrophysiology was successfully employed to
investigate drug interactions with P-type ATPases. In this respect,
the effects of various compounds of pharmacological interest
on SERCA pumping activity were characterized by SSM-based
current measurements (Tadini-Buoninsegni et al., 2008b, 2017;
Bartolommei et al., 2011; Ferrandi et al., 2013; Sadafi et al., 2014).
A molecular mechanism was proposed to explain the effect of
each compound, and the reaction step and/or intermediate of the
pump cycle affected by the drug was identified.
We point out that the SSM electrode combined with
robotized instrumentation is an attractive tool for drug
screening and development (Kelety et al., 2006). In this respect,
high-throughput devices capable of performing automated
measurements have been developed. For example, the SURFE2R
96SE device (Nanion Technologies, Munich, Germany) is able
to analyze 96 SSM sensors in a fully parallel mode allowing
determination of the dose dependence of 100 compounds in
<30min (Bazzone et al., 2017).
PHARMACOLOGICAL INHIBITORS OF
SERCA ACTIVITY
Various SERCA inhibitors with a variety of chemical structures
are known (Michelangeli and East, 2011). These compounds
represent a very useful tool in studies of the SERCA catalytic and
transport mechanism. Using X-ray crystallography of SERCA-
inhibitor complexes (Toyoshima and Nomura, 2002; Olesen
et al., 2004; Obara et al., 2005; Moncoq et al., 2007; Laursen et al.,
2009), distinct SERCA conformational states were determined at
atomic resolution.
A very potent and highly selective inhibitor is thapsigargin
(TG), a sesquiterpene lactone derived from the plant Thapsia
garganica (Rasmussen et al., 1978). TG is the most widely
employed SERCA inhibitor (Michelangeli and East, 2011) and
can inhibit SERCA activity with an IC50 in the sub-nanomolar
range (Sagara and Inesi, 1991). Other specific SERCA inhibitors
are cyclopiazonic acid (CPA) (Seidler et al., 1989), a secondary
metabolite from certain fungi, and the synthetic compound
2,5-di(tert-butyl)hydroquinone (DBHQ) (Moore et al., 1987).
Mutational analysis and crystallographic data have shown
that CPA and DBHQ occupy the same binding pocket at
the cytoplasmic ends of the transmembrane helices TM1–
TM4, while TG binds in a groove delimited by TM3, TM5,
and TM7 (for a review see Yatime et al., 2009), where the
residue Phe256 plays a fundamental role for both binding and
inhibitory effect of TG (Xu et al., 2004). TG, CPA, and DBHQ
(Table 1) affect SERCA transport activity in a similar way. These
inhibitors bind to SERCA in a calcium-free E2 conformation
and stabilize a compact ATPase conformational state (dead-
end state), preventing cytoplasmic calcium binding and catalytic
activation (Inesi et al., 2005; Yatime et al., 2009; Michelangeli and
East, 2011).
The inhibitory effects of TG, CPA, DBHQ, and1,3-dibromo-
2,4,6-tris (methyl-isothio-uronium) benzene (Br2-TITU),
another SERCA inhibitor (Berman and Karlish, 2003), on
Ca2+-ATPase transport activity were also characterized
by electrophysiological measurements on a SSM (Tadini-
Buoninsegni et al., 2008b). In this study it was shown that
Br2-TITU displays an inhibitory mechanism different from that
of TG, CPA, and DBHQ. In particular, it was demonstrated that
the inhibitory effect of Br2-TITU is related to kinetic interference
with a conformational transition of the phosphorylated
intermediate (E1P-Ca2 to E2P transition).
It is noteworthy that TG-related prodrugs are being evaluated
as anticancer drugs. Since TG will inhibit SERCA proteins
regardless of the cell type thereby damaging intracellular calcium
homeostasis not only in cancer cells but also in normal cells, its
high cytotoxicity prevents direct use of TG as a general antitumor
agent. However, a TG-based prodrug strategy was developed
to overcome the above-mentioned limitation (Denmeade et al.,
2012; Andersen et al., 2015; Doan et al., 2015; Cui et al.,
2017). In particular, a prodrug, namedmipsagargin, was obtained
by conjugating a TG analog to a peptide that is targeted
by prostate-specific membrane antigen (PSMA) (Denmeade
et al., 2012; Andersen et al., 2015; Doan et al., 2015), which
is overexpressed in prostate cancer cells and most tumor
endothelial cells. This inactive and non-toxic prodrug becomes
activated once it reaches tumor cells and the specific peptide
sequence is cleaved by PSMA, thereby releasing the active
cytotoxic TG analog. The prodrug mipsagargin can therefore be
considered as a potential therapeutic agent for the treatment of
various types of cancer, including prostate, breast and bladder
cancers.
In the context of antitumor agents, SSM-based
electrophysiology was employed to analyze the interaction
of metal-based anticancer drugs with P-type ATPases, i.e.,
SERCA, Na+,K+-ATPase and Cu+-ATPases (Sadafi et al.,
2014; Tadini-Buoninsegni et al., 2014, 2017). In particular, the
inhibitory effect of cisplatin (Table 1) on the transport activity
of SERCA and Na+,K+-ATPase was very recently investigated
(Figure 2) (Tadini-Buoninsegni et al., 2017). Cisplatin is a
platinum-containing anticancer drug, which is widely employed
as a chemotherapeutic agent against several tumors (Wang
and Lippard, 2005). However, cisplatin administration causes
inevitable adverse effects, which include nephrotoxicity,
ototoxicity and neurotoxicity. We have shown that cisplatin
is able to inhibit ATP-dependent cation translocation by
SERCA and Na+,K+-ATPase with different degrees of potency
(Figure 2). In particular, cisplatin was found to be a much
stronger inhibitor of SERCA (IC50 of 1.3µM) than of Na
+,K+-
ATPase (IC50 of 11.1µM). We propose that cisplatin inhibition
of SERCA and Na+,K+-ATPase activities may be relevant to
the molecular mechanisms that underlie the various adverse
effects of cisplatin and other platinum-containing anticancer
drugs.
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TABLE 1 | SERCA inhibitors and activators cited in the text.
Compounds Main properties and therapeutic applications References
Inhibitors Thapsigargin (TG) Very potent and highly selective inhibitor. TG-related prodrugs as
anticancer drugs.
Sagara and Inesi, 1991; Denmeade et al.,
2012; Doan et al., 2015
Cyclopiazonic acid (CPA) Potent and specific inhibitor. Cardioprotective effect. CPA derivatives as
antimalarial agents.
Seidler et al., 1989; Avellanal et al., 1998;
Moncoq et al., 2007; Cardi et al., 2010
2,5-di(tert-butyl)hydroquinone (DBHQ) Specific inhibitor. Moore et al., 1987; Obara et al., 2005
1,3-dibromo-2,4,6-tris
(methyl-isothio-uronium) benzene
(Br2-TITU)
SERCA and Na+,K+-ATPase inhibitor. Berman and Karlish, 2003
Cisplatin Widely employed platinum-containing anticancer drug. SERCA and
Na+,K+-ATPase inhibitor.
Wang and Lippard, 2005;
Tadini-Buoninsegni et al., 2017
Curcumin Antioxidant, anti-inflammatory and anticancer effects. Antimalarial
activity.
Bilmen et al., 2001; Reddy et al., 2005;
Schaffer et al., 2015
Activators Istaroxime Cardiac drug with inotropic and lusotropic properties. Stimulatory effect
on cardiac SERCA2a isoform. Therapeutic applications in acute and
chronic heart failure.
Rocchetti et al., 2005; Micheletti et al.,
2007; Gheorghiade et al., 2011; Ferrandi
et al., 2013
Pyridone derivative Stimulatory effect on cardiac SERCA2a isoform. Potential therapeutic
applications in heart failure.
Kaneko et al., 2017
CDN1163 Allosteric SERCA activator. Potential pharmacological agent for
diabetes and metabolic dysfunction.
Cornea et al., 2013; Gruber et al., 2014;
Kang et al., 2016
As concerns other specific inhibitors of SERCA activity,
CPA has been proposed to have therapeutic properties. In a
study of the isolated rabbit heart CPA was found to have a
cardioprotective effect on myocardial ischemia (Avellanal et al.,
1998). The mechanism involved in CPA cardioprotection is not
fully understood and could be partly attributed to a decreased
SR calcium contribution to the calcium overload induced by
ischemia.
It is noteworthy that CPA has been found to be a potent
inhibitor of the SERCA ortholog PfATP6 of Plasmodium
falciparum (Cardi et al., 2010; Arnou et al., 2011), the
protozoan parasite causing malaria which is responsible for most
malaria-related deaths globally. Considering that the parasite
P. falciparum is becoming increasingly resistant to some of
the most commonly used antimalarial drugs, PfATP6 has been
validated as a potential and promising target for the development
of new and effective antimalarials. PfATP6 and mammalian
SERCA are characterized by a different pharmacological profile:
compared to rabbit SERCA1a isoform from the skeletal muscle,
PfATP6 is less sensitive to TG and DBHQ and exhibits a
much higher affinity for CPA (Cardi et al., 2010; Arnou et al.,
2011). Moreover, it was shown that PfATP6 is not inhibited
by the widely employed antimalarial drug artemisinin (Cardi
et al., 2010; Arnou et al., 2011), which was proposed to target
PfATP6 (Eckstein-Ludwig et al., 2003). In a recent study, the
interaction of CPA with PfATP6 and SERCA was characterized
by molecular dynamics simulations (Di Marino et al., 2015).
This study points to significant differences in the mode of CPA
binding to the plasmodial and mammalian SERCA. These are
useful information that can assist in the design and development
of CPA derivatives, which are selective toward PfATP6 and with
a reduced activity against mammalian SERCA. Besides PfATP6,
the P. falciparum protein PfATP4, a P-type Na+-ATPase in the
plasma membrane of the parasite, has emerged as a potential
antimalarial drug target and inhibition of this pump is also
being considered as a possible treatment against malaria (Turner,
2016).
Among SERCA inhibitors of pharmacological interest, it
is worth mentioning the polyphenolic compound curcumin
(Table 1). Curcumin, which is obtained from the spice turmeric,
is known for its antioxidant, anti-inflammatory and anticancer
effects (Schaffer et al., 2015). It was reported that curcumin
inhibits SERCA activity with an IC50 in the micromolar range
(Bilmen et al., 2001; Dao et al., 2016) by stabilizing the E1
conformational state of SERCA and preventing ATP binding
and ATP-dependent phosphoenzyme formation (Bilmen et al.,
2001). In the search for new antimalarial agents, curcumin
was shown to possess a remarkable antiplasmodial activity,
as demonstrated by the inhibitory effects of curcumin on a
chloroquine-resistant P. falciparum strain (Reddy et al., 2005). It
was proposed that the PfATP6 protein could be a possible target
for curcumin antimalarial action (Reddy et al., 2005). In a very
recent study, selected curcumin analogs were synthesized and
their antimalarial activity against different P. falciparum strains
was evaluated (Dohutia et al., 2017). In particular, molecular
docking was performed to investigate the interaction of these
curcumin analogs with PfATP6. The results of this study may
provide useful information for the development of curcumin
derivatives which could serve as promising drug candidates
against malaria.
PHARMACOLOGICAL STIMULATION OF
SERCA ACTIVITY
Molecules that are able to stimulate SERCA activity have
been recently identified (Table 1). A remarkable example
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FIGURE 2 | Upper Panel: SERCA current signals induced by 100µM ATP
concentration jumps in the presence of 10µM free Ca2+ and in the absence
(control measurement, solid line, a) or in the presence of 5µM cisplatin (dotted
line, b). (Inset) Normalized charges (QN) related to ATP concentration jumps in
the presence of Ca2+ ions as a function of cisplatin concentration. The
charges are normalized with reference to the maximum charge attained in the
absence of cisplatin (control measurement). The solid line represents the fitting
curve to the ATP-induced charges (IC50 = 1.3 ± 0.1µM). The error bars
represent S.E. of three independent measurements. Lower Panel:
Na+,K+-ATPase current signals induced by 100µM ATP concentration jumps
in the presence of 80mM NaCl and 50mM KCl, and in the absence (control
measurement, solid line, a) or in the presence of 5µM cisplatin (dotted line, b).
(Inset) Normalized charges (QN) related to ATP concentration jumps in the
presence of Na+ and K+ ions as a function of cisplatin concentration. The
charges are normalized with respect to the maximum charge measured in the
absence of cisplatin (control measurement). The solid line represents the fitting
curve to the ATP-induced charges (IC50 = 11.1 ± 0.8µM). The error bars
represent S.E. of three independent measurements. Tadini-Buoninsegni et al.
(2017)—Reproduced by permission of The Royal Society of Chemistry.
of SERCA activators is the drug istaroxime. Istaroxime
is an innovative cardiac drug which combines inotropic
(cardiomyocyte contraction) and lusotropic (cardiomyocyte
relaxation) properties (Hasenfuss and Teerlink, 2011). Istaroxime
has a double mechanism of action, i.e., it inhibits Na+,K+-
ATPase activity and exerts a stimulatory effect on SERCA2a
(Micheletti et al., 2002, 2007; Rocchetti et al., 2005, 2008),
the SERCA isoform in the heart which is central to cardiac
electrophysiological and mechanical function. Preclinical studies
and clinical trials indicate that combining SERCA2a stimulation
and Na+,K+-ATPase inhibition may increase contractility
and facilitate active relaxation, improving both systolic and
diastolic heart function (Gheorghiade et al., 2011). The
stimulatory effect of istaroxime on SERCA activity was
investigated by combining different experimental methods,
including electrophysiological measurements on dog cardiac SR
vesicles adsorbed to a SSM (Ferrandi et al., 2013). This study
shows that istaroxime enhances SERCA2a activity, Ca2+ uptake,
and Ca2+-dependent charge movements into SR vesicles from
healthy or failing dog hearts. It was proposed that istaroxime acts
by displacing the regulatory protein phospholamban (PLN) from
the SERCA2a/PLN complex, thereby removing the inhibitory
effect of PLN on this complex. Displacement of PLN from
SERCA2a may favor the SERCA2a conformational transition E2
to E1, thus accelerating Ca
2+ cycling. Istaroxime with its unique
mode of action may provide a new small-molecule therapeutics
for the treatment of both acute and chronic heart failure.
Very recently, a pyridone derivative was reported to
activate the SERCA2a isoform by attenuating the inhibitory
effect of PLN (Kaneko et al., 2017). In vitro and in vivo
experiments have demonstrated that the pyridone derivative
stimulates the Ca2+-dependent ATPase activity of cardiac
SR vesicles, increases Ca2+ transients of isolated adult rat
cardiomyocytes and accelerates contraction and relaxation of
isolated perfused rat hearts. It was concluded that the pyridone
derivative behaves like a SERCA2a activator, which binds and
inhibits PLN, and enhances systolic and diastolic functions
of the heart. The pyridone derivative is thus proposed as a
novel lead compound for therapeutic applications in heart
failure.
Impaired SERCA function leads to elevation of intracellular
calcium concentration and alterations in calcium homeostasis,
which trigger endoplasmic reticulum (ER) stress. ER stress is
associated with a variety of common diseases (Oyadomari and
Mori, 2004), including the metabolic syndrome and type 2
diabetes (Back and Kaufman, 2012). Pharmacological activation
of SERCA can reduce ER stress and may therefore represent
a novel strategy for the treatment of diabetes and metabolic
disorders. A recent study (Kang et al., 2016) evaluated the
metabolic effects of the quinoline-amide compound CDN1163,
which is a novel SERCA activator (Cornea et al., 2013;
Gruber et al., 2014). CDN1163 directly binds to the SERCA
enzyme to activate Ca2+-ATPase activity, probably via an
allosteric mechanism (Cornea et al., 2013; Gruber et al., 2014).
Kang et al. (2016) demonstrated that CDN1163 activation
of the SERCA2b isoform from mouse liver reduces ER
stress and improves mitochondrial efficiency and metabolic
parameters in an animal model of insulin resistance and type
2 diabetes (ob/ob mice), suggesting that SERCA activators may
represent promising pharmacological agents to treat diabetes
and metabolic dysfunction. Finally, since defective SERCA is a
significant cause of ER stress and neuron loss in Parkinson’s
disease, direct activation of SERCA by small-molecule drugs
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is currently explored as a viable strategy to develop a novel
therapeutic approach to cure Parkinson’s disease (Dahl, 2017).
CONCLUSIONS
SERCA plays an essential role in the maintenance of cellular
calcium homeostasis and calcium pump malfunction is
associated to severe disorders and several pathophysiological
conditions. Therefore, the SERCA enzyme represents an
important target for the development of new drugs. SERCA
inhibitors have been identified as potential drug candidates
against various diseases. As discussed above, inhibition of
SERCA activity in cancer cells provides an alternative therapeutic
approach to cure different types of cancer. Moreover, specific
inhibitors targeting the SERCA ortholog PfATP6 in the parasite
P. falciparum may serve as innovative and effective antimalarial
agents. In addition, studies on novel SERCA activators indicate
that pharmacological activation of SERCA may constitute
a promising strategy for the treatment of heart failure and
diabetes. Research effort is devoted to the synthesis of highly
selective and potent drugs, that can target SERCA in a tissue-
specific manner. As most tissue/cell types can express more than
one SERCA isoform, it would be highly desirable, although very
challenging, to develop isoform-specific drugs that can interact
selectively with one SERCA isoform, leaving the other protein
molecules intact (Yatime et al., 2009; Michelangeli and East,
2011).
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